You are here

Development of a MSP1-p42 Subunit Vaccine for Malaria

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N/A
Agency Tracking Number: 2R44AI043119-02A2
Amount: $0.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2001
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
99-193 AIEA HEIGHTS DR, STE 236
AIEA, HI 96701
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DAVID CLEMENTS
 () -
Business Contact
Phone: (808) 486-5333
Email: STAFF@HIBIOTECH.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by the applicant): Malaria is a tropical parasitic
disease that poses a significant health threat to much of the world. Each year,
approximately 500 million people become infected and more than 2 million die.
There is a great need to control the spread of this disease. One of the main
focuses of malaria vaccine development has been the on use of recombinant
proteins derived from the various developmental stages of the parasite. The
goal of the proposed research is to produce highly immunogenic recombinant
subunits that can be formulated with clinically relevant adjuvants in an effort
to advance candidate vaccine antigens from preclinical status to clinical
status. Phase I research demonstrated that the MSP-1 p42 antigen is expressed
at high levels in the Drosophila cell expression system. The expressed antigen
has been demonstrated to have relevant antigenic and immunogenic properties
associated with native structure. Phase II research will further characterize
the immunogenic properties of the abundantly expressed p42. The ability of the
p42 antigen to provide a protective response in monkeys when formulated with
clinically relevant antigens will be tested. The success of the proposed
research would result in a product that could then be tested in humans.
PROPOSED COMMERCIAL APPLICATIONS:
Malaria poses a significant world-wide health threat. Currently, there is no vaccine for malaria. The proposed research will test the efficacy of a malaria vaccine candidate protein subunits to elicit protective responses in Aotus monkeys when formulated with clinically relevant adjuvants. The ability of this antigen to provide a protective response when formulated with one or more clinically relevant adjuvant would contribute to the development of a safe, efficacious and cost effective malaria vaccine.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government